UPDATE: Stifel Nicolaus Raises PT to $20 on Sabra Health Care REIT on Enhanced Acquisition Visibility

Loading...
Loading...
Stifel Nicolaus reiterated its Buy rating on Sabra Health Care REIT
SBRA
and raised its price target from $17 to $20. Stifel Nicolaus commented, "We are raising our price target for Sabra Health Care REIT from $17 to $20 as we expect accretive investment activity to ramp up given its targets' success in restoring margins affected by last year's Medicare rate cuts. We believe that the operators of skilled nursing facilities (SNFs) have mitigated last October's 11.1% Medicare rate cut and are now in a position to monetize real estate assets. An uptick in accretive acquisitions over the pace of the first half of the year would enable Sabra to sustain above-average growth." Sabra Health Care REIT closed at $17.89 on Friday.
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetIntraday UpdateAnalyst RatingsStifel Nicolaus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...